Dose-dependent antiviral effects of glycyrrhizin, curcumin, and harmaline against clinical SARS-CoV-2 isolates, including D614G, Omicron BA.5, and Omicron XBB.1
Our findings support the potential of glycyrrhizin, curcumin, and harmaline as variant-independent treatment candidates for COVID-19. However, further clinical studies are necessary to validate their efficacy and safety in vivo.
Authors
- C. Elsner
- Ulf Dittmer (ORCID: https://orcid.org/0000-0001-9284-4849)
- Adalbert Krawczyk (ORCID: https://orcid.org/0000-0001-9502-9903)
- O. Witzke
- E. Scheiermann
- Laura Thümmler (ORCID: https://orcid.org/0000-0003-2034-6255)
- Ivana Kraiselburd (ORCID: https://orcid.org/0000-0002-9677-6094)
- Isabel Zydek
- Folker Meyer
- Rabea Grüneberg
- Hana Rohn
Institutions
- Essen University Hospital (DE)
- West German Heart and Vascular Center Essen (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- BMC Complementary Medicine and Therapies
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1186/s12906-026-05253-1
- Primary Topic
- Tea Polyphenols and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00